Pressure BioSciences, Inc.
PBIO · OTC
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Revenue | $422 | $349 | $312 | $413 |
| % Growth | 20.8% | 11.8% | -24.4% | – |
| Cost of Goods Sold | -$421,370 | $233 | $334 | $642 |
| Gross Profit | $44 | $116 | -$21 | -$229 |
| % Margin | 10.5% | 33.2% | -6.8% | -55.6% |
| R&D Expenses | $296 | $272 | $363 | $288 |
| G&A Expenses | $1,520 | $1,198 | $2,914 | $1,030 |
| SG&A Expenses | $1,677 | $1,328 | $3,107 | $1,188 |
| Sales & Mktg Exp. | $157 | $130 | $193 | $158 |
| Other Operating Expenses | $0 | $0 | $0 | $8 |
| Operating Expenses | $1,973 | $1,601 | $3,470 | $1,476 |
| Operating Income | -$1,929 | -$1,485 | -$3,491 | -$1,706 |
| % Margin | -457.2% | -425.1% | -1,117.7% | -413% |
| Other Income/Exp. Net | -$5,188 | -$6,590 | -$6,413 | -$4,337 |
| Pre-Tax Income | -$7,116 | -$8,074 | -$9,904 | -$6,262 |
| Tax Expense | $0 | $0 | $0 | -$28 |
| Net Income | -$7,116 | -$8,074 | -$9,904 | -$6,262 |
| % Margin | -1,687.2% | -2,311.9% | -3,170.7% | -1,516.2% |
| EPS | -0.15 | -0.22 | -0.44 | -0.288 |
| % Growth | 31.8% | 50% | -52.6% | – |
| EPS Diluted | -0.15 | -0.22 | -0.44 | -0.288 |
| Weighted Avg Shares Out | 51,412 | 39,812 | 22,527 | 21,717 |
| Weighted Avg Shares Out Dil | 51,412 | 39,812 | 22,527 | 21,717 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $0 | $0 | $0 |
| Interest Expense | $3,535 | $5,385 | $1,469 | $4,339 |
| Depreciation & Amortization | $90 | $76 | $28 | $28 |
| EBITDA | -$3,492 | -$2,614 | -$3,463 | -$1,263 |
| % Margin | -827.9% | -748.3% | -1,108.7% | -305.8% |